(SRRK) – Company Press Releases
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
-
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
-
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
-
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2024
-
Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress
-
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
-
Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting
-
Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
-
Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock
-
Scholar Rock Announces Proposed Public Offering of Common Stock
-
Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders
-
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Present at the Jefferies Healthcare Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress
-
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
-
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
-
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
-
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
-
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
-
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
Back to SRRK Stock Lookup
